A5000559240- Pharmaceutical Practices and Patient Outcomes
- Patient Safety and Medication Errors
- COVID-19 Clinical Research Studies
- Drug-Induced Hepatotoxicity and Protection
- SARS-CoV-2 and COVID-19 Research
- Children's Physical and Motor Development
- Cerebral Palsy and Movement Disorders
- Pharmacological Receptor Mechanisms and Effects
- Pharmacy and Medical Practices
- Pharmacological Effects and Toxicity Studies
- Clinical Nutrition and Gastroenterology
- Drug Transport and Resistance Mechanisms
- Infant Development and Preterm Care
- Pharmaceutical studies and practices
- Eosinophilic Esophagitis
- Atrial Fibrillation Management and Outcomes
- Intestinal and Peritoneal Adhesions
- Venous Thromboembolism Diagnosis and Management
- Intestinal Malrotation and Obstruction Disorders
- Healthcare Decision-Making and Restraints
- Emergency and Acute Care Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Antibiotics Pharmacokinetics and Efficacy
- Long-Term Effects of COVID-19
Haga Hospital
2018-2023
Erasmus MC
2019
Heliomare
2011
Isala
2007
We report a case of man with COVID-19 who developed acute hepatotoxicity related to remdesivir probable interaction P-glycoprotein (P-gp) inhibitors. Until further details on this become available, we recommend physicians be cautious the prescription P-gp inhibitors in patients receiving therapy.
Medication errors occur frequently in the intensive care unit (ICU) and during transitions. Chronic medication is often temporarily stopped at ICU. Unfortunately, when patient improves, restart of this easily forgotten. Moreover, temporal ICU unintentionally continued after discharge. reconciliation could be useful to prevent such errors. Therefore, aim study was determine effect ICU.This prospective 8-month with a pre- post-design carried out two settings Netherlands. Patients were included...
The objective of this study was to describe the population pharmacokinetics remdesivir and GS-441524 in hospitalized coronavirus disease 2019 (COVID-19) patients. A prospective observational pharmacokinetic performed non-critically ill COVID-19 patients with hypoxemia. For evaluation plasma concentrations its metabolite GS-441524, samples were collected on first day therapy. nonlinear mixed-effects model developed identify potential covariates that explain variability. Alternative dosing...
Discharge from the intensive care unit (ICU) is a high-risk process, leading to numerous potentially harmful medication transfer errors (PH-MTE). PH-MTE could be prevented by reconciliation ICU pharmacists, but resources are scarce, which renders need for predicting patients at risk PH-MTE. The aim of this study was develop prognostic multivariable model in discharged predict who increased after discharge, using predictors that readily available time discharge.Data were derived Transfer...
Remdesivir is a registered treatment for hospitalised patients with COVID-19 that has moderate clinical effectiveness. Anecdotally, some patients' respiratory insufficiency seemed to recover particularly rapidly after initiation of remdesivir. In this study, we investigated if rapid improvement was caused by remdesivir, and which patient characteristics might predict in response This multicentre observational cohort study who required supplemental oxygen were treated dexamethasone. Rapid...